Discontinuation report ERYC DELAYED-RELEASE CAPSULES
Report ID | 95138 |
Drug Identification Number | 00607142 |
Brand name | ERYC DELAYED-RELEASE CAPSULES |
Common or Proper name | Eryc |
Company Name | PFIZER CANADA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | ERYTHROMYCIN |
Strength(s) | 250MG |
Dosage form(s) | CAPSULE (ENTERIC-COATED) |
Route of administration | ORAL |
Packaging size | 1 x 100s |
ATC code | J01FA |
ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2020-04-01 |
Actual discontinuation date | 2020-04-07 |
Remaining supply date | 2020-04-01 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | Eryc 333mg 1x100s presentation remains available |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2019-10-01 | English | Compare |
v2 | 2019-10-01 | French | Compare |
v3 | 2020-04-13 | English | Compare |
v4 | 2020-04-13 | French | Compare |
Showing 1 to 4 of 4